These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35117689)

  • 21. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
    Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
    Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
    [No Abstract]   [Full Text] [Related]  

  • 22. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
    García Campelo MR; Arriola E; Campos Balea B; López-Brea M; Fuentes-Pradera J; de Castro Carpeno J; Aguado C; Pérez Parente D; de Oro Pulido F; Ruiz-Gracia P; Rodríguez-Abreu D
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
    Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
    Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
    Wang PF; Chen Y; Song SY; Wang TJ; Ji WJ; Li SW; Liu N; Yan CX
    Front Pharmacol; 2017; 8():730. PubMed ID: 29093678
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
    De Velasco G; Je Y; Bossé D; Awad MM; Ott PA; Moreira RB; Schutz F; Bellmunt J; Sonpavde GP; Hodi FS; Choueiri TK
    Cancer Immunol Res; 2017 Apr; 5(4):312-318. PubMed ID: 28246107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Deng S; Yang Q; Shu X; Lang J; Lu S
    Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
    [No Abstract]   [Full Text] [Related]  

  • 35. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis.
    Xie R; Wu J; Shang B; Bi X; Cao C; Guan Y; Shi H; Shou J
    Cancer Innov; 2022 Dec; 1(4):293-304. PubMed ID: 38089086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
    J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
    Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
    Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.